Novavax Inc Total Assets
Novavax Inc total assets. Based on the latest financial reports, Novavax Inc (NVAX) holds total assets worth $955.58 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Novavax Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Novavax Inc (1996–2025)
Total assets of Novavax Inc from 1996 to 2025. This chart illustrates how Novavax Inc's total assets have evolved over time, based on quarterly financial data. See NVAX share price today for real-time trading data and today's change.
Novavax Inc - Asset Composition Analysis
Novavax Inc Total Assets Breakdown (December 2025)
Novavax Inc total assets breakdown as of December 2025. Novavax Inc's total assets of $955.58 Million consist of 83.2% current assets and 16.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.5% |
| Accounts Receivable | $106.45 Million | 9.1% |
| Inventory | $11.54 Million | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $113.46 Million | 9.6% |
Asset Composition Trend (1996–2025)
This chart illustrates how Novavax Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Novavax Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novavax Inc's current assets represent 83.2% of total assets in 2025, an increase from 56.1% in 1996.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 43.9% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 9.6% of total assets.
Novavax Inc Competitors by Total Assets
Key competitors of Novavax Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Novavax Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 2.36 | 1.24 |
| Quick Ratio | 2.30 | 2.34 | 1.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $440.52 Million | $530.37 Million | $420.77 Million |
Novavax Inc - Advanced Valuation Insights
This section examines the relationship between Novavax Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.23 |
| Latest Market Cap to Assets Ratio | 1.11 |
| Asset Growth Rate (YoY) | -24.6% |
| Total Assets | $1.18 Billion |
| Market Capitalization | $1.31 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novavax Inc's assets above their book value (1.11x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Novavax Inc's assets decreased by 24.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novavax Inc (1996–2025)
The table below shows the annual total assets of Novavax Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.18 Billion | -24.60% |
| 2024-12-31 | $1.56 Billion | -13.19% |
| 2023-12-31 | $1.80 Billion | -20.42% |
| 2022-12-31 | $2.26 Billion | -12.34% |
| 2021-12-31 | $2.58 Billion | +62.83% |
| 2020-12-31 | $1.58 Billion | +814.96% |
| 2019-12-31 | $172.96 Million | -16.84% |
| 2018-12-31 | $207.98 Million | -31.25% |
| 2017-12-31 | $302.49 Million | -23.28% |
| 2016-12-31 | $394.30 Million | +2.14% |
| 2015-12-31 | $386.04 Million | +39.87% |
| 2014-12-31 | $276.00 Million | +16.98% |
| 2013-12-31 | $235.94 Million | +130.53% |
| 2012-12-31 | $102.34 Million | +53.73% |
| 2011-12-31 | $66.58 Million | -11.05% |
| 2010-12-31 | $74.84 Million | -12.57% |
| 2009-12-31 | $85.61 Million | +11.72% |
| 2008-12-31 | $76.62 Million | -16.07% |
| 2007-12-31 | $91.29 Million | -25.10% |
| 2006-12-31 | $121.88 Million | +44.43% |
| 2005-12-31 | $84.38 Million | +8.19% |
| 2004-12-31 | $77.99 Million | -7.33% |
| 2003-12-31 | $84.16 Million | +46.35% |
| 2002-12-31 | $57.51 Million | -14.32% |
| 2001-12-31 | $67.11 Million | +18.73% |
| 2000-12-31 | $56.53 Million | +1156.20% |
| 1999-12-31 | $4.50 Million | +18.42% |
| 1998-12-31 | $3.80 Million | -44.12% |
| 1997-12-31 | $6.80 Million | +19.30% |
| 1996-12-31 | $5.70 Million | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more